- AVXL Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Anavex Life Sciences (AVXL) CORRESPCorrespondence with SEC
Filed: 22 Jul 14, 12:00am
ANAVEX LIFE SCIENCES CORP.
51 W. 52nd Street, 7th Floor
New York, NY 10019-6163
July 22, 2014
VIA EDGAR
Mr. Jeffrey P. Riedler
Assistant Director
United States Securities and Exchange Commission
100 F. Street, N.E.
Mail Stop 3561
Washington, DC 20549
Re: | Anavex Life Sciences Corp. |
Request for Acceleration of Registration Statement on Form S-1 | |
File No. 333-195225 |
Dear Mr. Riedler:
In accordance with Rule 461 under the Securities Act of 1933, Anavex Life Sciences Corp., a Nevada corporation (the “Company”), hereby requests acceleration of the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-195225) (the “RegistrationStatement”), which was initially filed with the Securities and Exchange Commission (the “Commission”) on April 11, 2014 and amended on July 10, 2014. The Company respectfully requests that the Registration Statement become effective as of 5:00 p.m., Washington, D.C. time, on July 23, 2014, or as soon as practicable thereafter.
The Company acknowledges the following:
Please direct any questions or comments regarding this filing to John D. Owens III, Esq. at (305) 539-3328 of K&L Gates LLP, outside securities counsel to the Company.
Very truly yours, | |
/s/Christopher Missling, PhD | |
Christopher Missling, PhD | |
Chief Exectuive Officer |
Cc: Austin Stephenson, United States Securities and Exchange Commission
- 2 -